Kezar Life Sciences
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
4000 Shoreline Ct Ste 300, South San Fra...Phone Number
(650) 822-5600Website
www.kezarlifesciences.comRevenue
-Stock Symbol
KZRIndustry
About Kezar Life Sciences
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Explore more
Kezar Life Sciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Kezar Life Sciences
Compare insights from companies similar to Kezar Life Sciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Kezar Life Sciences Tech Stack
A closer look at the technologies used by Kezar Life Sciences
See more technologies
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Kezar Life Sciences
Sign Up For FreeTo access detailed company insights
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b... Read More
